Other Events ·
Benitec Biopharma appoints Ernst & Young as independent auditor following routine governance review
BNTCBenitec Biopharma Inc.
Benitec Biopharma Inc. dismissed Baker Tilly US, LLP as its independent registered public accounting firm and appointed Ernst & Young LLP (EY) to serve in that capacity for the fiscal year ending June 30, 2027. The change was made following a routine governance review by the Audit Committee, with no disagreements on accounting principles or reportable events cited between the company and Baker Tilly. A prior material weakness regarding share-based compensation controls reported in the 2025 annual report was remediated as of June 30, 2026. Benitec Biopharma Inc. operates in the biotechnology industry, focusing on developing nucleic acid therapeutics for genetic diseases.